View ValuationStraumann Holding 향후 성장Future 기준 점검 4/6Straumann Holding (는) 각각 연간 16.8% 및 9.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 22.1% 로 예상됩니다.핵심 정보16.8%이익 성장률16.95%EPS 성장률Medical Equipment 이익 성장12.6%매출 성장률9.7%향후 자기자본이익률22.09%애널리스트 커버리지Good마지막 업데이트21 Aug 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Aug 21Straumann Holding AG Announces CEO ChangesStraumann Holding AG announced that its Chief Executive Officer Guillaume Daniellot would step down. The company appointed Christopher Norbye as CEO, effective December 1, 2026, as part of a planned leadership transition. Guillaume Daniellot would step down after nearly 20 years with the company. Norbye joined the company from Beijer Ref AB as CEO and previously led ASSA ABLOY. Daniellot would complete his term at the end of November and support the transition, including work with key customers. Norbye would join Straumann in October to facilitate the handover.Reported Earnings • Aug 20First half 2026 earnings released: EPS: CHF1.57 (vs CHF1.49 in 1H 2025)First half 2026 results: EPS: CHF1.57 (up from CHF1.49 in 1H 2025). Revenue: CHF1.38b (up 2.3% from 1H 2025). Net income: CHF249.7m (up 5.3% from 1H 2025). Profit margin: 18% (in line with 1H 2025). Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in Italy.공고 • Aug 19Straumann Holding AG to Report Q3, 2026 Results on Oct 28, 2026Straumann Holding AG announced that they will report Q3, 2026 results on Oct 28, 2026Valuation Update With 7 Day Price Move • Aug 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €100.00, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 21x in the Medical Equipment industry in Italy. Total loss to shareholders of 4.6% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €134 per share.Buy Or Sell Opportunity • Aug 07Now 26% undervaluedOver the last 90 days, the stock has risen 10% to €103. The fair value is estimated to be €138, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.Buy Or Sell Opportunity • Jul 03Now 20% undervaluedOver the last 90 days, the stock has risen 32% to €120. The fair value is estimated to be €151, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.6% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.공고 • Jun 17Straumann Holding AG to Report First Half, 2026 Results on Aug 19, 2026Straumann Holding AG announced that they will report first half, 2026 results on Aug 19, 2026Valuation Update With 7 Day Price Move • May 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €99.50, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 19x in the Medical Equipment industry in Italy. Total loss to shareholders of 13% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €136 per share.Buy Or Sell Opportunity • May 21Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to €86.50. The fair value is estimated to be €119, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.Board Change • May 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Honorary Chairman Thomas Straumann was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • May 06Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €102, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 18x in the Medical Equipment industry in Italy. Total loss to shareholders of 3.6% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €142 per share.Board Change • May 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Honorary Chairman Thomas Straumann was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Large one-off items impacting financial results.Buy Or Sell Opportunity • Apr 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to €91.00. The fair value is estimated to be €114, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.공고 • Apr 09Straumann Holding AG to Report Q1, 2026 Results on Apr 29, 2026Straumann Holding AG announced that they will report Q1, 2026 results at 7:00 AM, Central European Standard Time on Apr 29, 2026공고 • Mar 17Straumann Holding AG, Annual General Meeting, Apr 17, 2026Straumann Holding AG, Annual General Meeting, Apr 17, 2026, at 10:00 W. Europe Standard Time.Buy Or Sell Opportunity • Mar 06Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.5% to €94.50. The fair value is estimated to be €119, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.New Risk • Feb 21New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.Reported Earnings • Feb 20Full year 2025 earnings released: EPS: CHF2.24 (vs CHF2.87 in FY 2024)Full year 2025 results: EPS: CHF2.24 (down from CHF2.87 in FY 2024). Revenue: CHF2.61b (up 4.1% from FY 2024). Net income: CHF356.7m (down 22% from FY 2024). Profit margin: 14% (down from 18% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Italy.공고 • Feb 19Straumann Holding AG announces Annual dividend, payable on April 23, 2026Straumann Holding AG announced Annual dividend of CHF 1.0000 per share payable on April 23, 2026, ex-date on April 21, 2026 and record date on April 22, 2026.Buy Or Sell Opportunity • Feb 01Now 21% overvaluedOver the last 90 days, the stock has fallen 5.6% to €102. The fair value is estimated to be €84.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 7.4% per annum. Earnings are also forecast to grow by 14% per annum over the same time period.공고 • Jan 19Straumann Holding AG to Report Fiscal Year 2025 Results on Feb 18, 2026Straumann Holding AG announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 18, 2026Buy Or Sell Opportunity • Jan 09Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to €108. The fair value is estimated to be €89.84, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 7.6% per annum. Earnings are also forecast to grow by 14% per annum over the same time period.Reported Earnings • Aug 14First half 2025 earnings released: EPS: CHF1.49 (vs CHF1.67 in 1H 2024)First half 2025 results: EPS: CHF1.49 (down from CHF1.67 in 1H 2024). Revenue: CHF1.35b (up 5.9% from 1H 2024). Net income: CHF237.2m (down 11% from 1H 2024). Profit margin: 18% (down from 21% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Italy.New Risk • Jul 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.이익 및 매출 성장 예측BIT:1STMN - 애널리스트 향후 추정치 및 과거 재무 데이터 (CHF Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20283,3356746048601412/31/20273,0375895197571612/31/20262,766496493722146/30/20262,637369339523N/A3/31/20262,621363310514N/A12/31/20252,605357281504N/A9/30/20252,592392292502N/A6/30/20252,579428303500N/A3/31/20252,541443310492N/A12/31/20242,504458316483N/A9/30/20242,455474320497N/A6/30/20242,406490325510N/A3/31/20242,341469321507N/A12/31/20232,277448317504N/A9/30/20232,282421285475N/A6/30/20232,286394253446N/A3/31/20232,304415236431N/A12/31/20222,321435220415N/A9/30/20222,268462264442N/A6/30/20222,215489308469N/A3/31/20222,118442374515N/A12/31/20212,022396439560N/A9/30/20211,914377466566N/A6/30/20211,806358492573N/A3/31/20211,616224393475N/A12/31/20201,42691295377N/A9/30/20201,42479240344N/A6/30/20201,42167185311N/A3/31/20201,509187N/A345N/A12/31/20191,596306N/A378N/A9/30/20191,529298N/A338N/A6/30/20191,462289N/A298N/A3/31/20191,413281N/A288N/A12/31/20181,364273N/A277N/A9/30/20181,307271N/A262N/A6/30/20181,250269N/A246N/A3/31/20181,181274N/A232N/A12/31/20171,112280N/A217N/A9/30/20171,056257N/A206N/A6/30/20171,000235N/A194N/A3/31/2017959232N/A189N/A12/31/2016918230N/A185N/A9/30/2016889218N/A188N/A6/30/2016861207N/A192N/A3/31/2016830139N/A189N/A12/31/201579971N/A186N/A9/30/201577479N/A175N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 1STMN 의 연간 예상 수익 증가율(16.8%)이 saving rate(3.4%)보다 높습니다.수익 vs 시장: 1STMN 의 연간 수익(16.8%)이 Italian 시장(10.1%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 1STMN 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 1STMN 의 수익(연간 9.7%)이 Italian 시장(연간 5.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 1STMN 의 수익(연간 9.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 1STMN의 자본 수익률은 3년 후 22.1%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/21 20:26종가2026/08/21 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Straumann Holding AG는 36명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert BateBarclaysHassan Al-WakeelBarclaysVictoria LambertBerenberg33명의 분석가 더 보기
공고 • Aug 21Straumann Holding AG Announces CEO ChangesStraumann Holding AG announced that its Chief Executive Officer Guillaume Daniellot would step down. The company appointed Christopher Norbye as CEO, effective December 1, 2026, as part of a planned leadership transition. Guillaume Daniellot would step down after nearly 20 years with the company. Norbye joined the company from Beijer Ref AB as CEO and previously led ASSA ABLOY. Daniellot would complete his term at the end of November and support the transition, including work with key customers. Norbye would join Straumann in October to facilitate the handover.
Reported Earnings • Aug 20First half 2026 earnings released: EPS: CHF1.57 (vs CHF1.49 in 1H 2025)First half 2026 results: EPS: CHF1.57 (up from CHF1.49 in 1H 2025). Revenue: CHF1.38b (up 2.3% from 1H 2025). Net income: CHF249.7m (up 5.3% from 1H 2025). Profit margin: 18% (in line with 1H 2025). Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in Italy.
공고 • Aug 19Straumann Holding AG to Report Q3, 2026 Results on Oct 28, 2026Straumann Holding AG announced that they will report Q3, 2026 results on Oct 28, 2026
Valuation Update With 7 Day Price Move • Aug 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €100.00, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 21x in the Medical Equipment industry in Italy. Total loss to shareholders of 4.6% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €134 per share.
Buy Or Sell Opportunity • Aug 07Now 26% undervaluedOver the last 90 days, the stock has risen 10% to €103. The fair value is estimated to be €138, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
Buy Or Sell Opportunity • Jul 03Now 20% undervaluedOver the last 90 days, the stock has risen 32% to €120. The fair value is estimated to be €151, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.6% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
공고 • Jun 17Straumann Holding AG to Report First Half, 2026 Results on Aug 19, 2026Straumann Holding AG announced that they will report first half, 2026 results on Aug 19, 2026
Valuation Update With 7 Day Price Move • May 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €99.50, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 19x in the Medical Equipment industry in Italy. Total loss to shareholders of 13% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €136 per share.
Buy Or Sell Opportunity • May 21Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to €86.50. The fair value is estimated to be €119, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
Board Change • May 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Honorary Chairman Thomas Straumann was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • May 06Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €102, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 18x in the Medical Equipment industry in Italy. Total loss to shareholders of 3.6% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €142 per share.
Board Change • May 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Honorary Chairman Thomas Straumann was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Large one-off items impacting financial results.
Buy Or Sell Opportunity • Apr 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to €91.00. The fair value is estimated to be €114, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
공고 • Apr 09Straumann Holding AG to Report Q1, 2026 Results on Apr 29, 2026Straumann Holding AG announced that they will report Q1, 2026 results at 7:00 AM, Central European Standard Time on Apr 29, 2026
공고 • Mar 17Straumann Holding AG, Annual General Meeting, Apr 17, 2026Straumann Holding AG, Annual General Meeting, Apr 17, 2026, at 10:00 W. Europe Standard Time.
Buy Or Sell Opportunity • Mar 06Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.5% to €94.50. The fair value is estimated to be €119, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
New Risk • Feb 21New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.
Reported Earnings • Feb 20Full year 2025 earnings released: EPS: CHF2.24 (vs CHF2.87 in FY 2024)Full year 2025 results: EPS: CHF2.24 (down from CHF2.87 in FY 2024). Revenue: CHF2.61b (up 4.1% from FY 2024). Net income: CHF356.7m (down 22% from FY 2024). Profit margin: 14% (down from 18% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Italy.
공고 • Feb 19Straumann Holding AG announces Annual dividend, payable on April 23, 2026Straumann Holding AG announced Annual dividend of CHF 1.0000 per share payable on April 23, 2026, ex-date on April 21, 2026 and record date on April 22, 2026.
Buy Or Sell Opportunity • Feb 01Now 21% overvaluedOver the last 90 days, the stock has fallen 5.6% to €102. The fair value is estimated to be €84.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 7.4% per annum. Earnings are also forecast to grow by 14% per annum over the same time period.
공고 • Jan 19Straumann Holding AG to Report Fiscal Year 2025 Results on Feb 18, 2026Straumann Holding AG announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 18, 2026
Buy Or Sell Opportunity • Jan 09Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to €108. The fair value is estimated to be €89.84, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 7.6% per annum. Earnings are also forecast to grow by 14% per annum over the same time period.
Reported Earnings • Aug 14First half 2025 earnings released: EPS: CHF1.49 (vs CHF1.67 in 1H 2024)First half 2025 results: EPS: CHF1.49 (down from CHF1.67 in 1H 2024). Revenue: CHF1.35b (up 5.9% from 1H 2024). Net income: CHF237.2m (down 11% from 1H 2024). Profit margin: 18% (down from 21% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Italy.
New Risk • Jul 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.